2022 ASCO Annual Meeting*

Download All
June 3-7, 2022; Chicago, Illinois
Expert faculty review and share their insights and perspectives on key findings in breast cancer and gynecologic cancers presented at the 2022 ASCO Annual Meeting.
Joyce O'Shaughnessy, MD
Angeles Alvarez Secord, MD, MHSc

Breast Cancer and Gynecologic Cancers

Slidesets FAKTION: Updated and Expanded Analysis of Fulvestrant + Capivasertib or Placebo After Aromatase Inhibitor Therapy in ER+/HER2- Advanced Breast Cancer
Slidesets KEYNOTE-522: Exploratory Analysis of EFS by Residual Cancer Burden With Neoadjuvant Pembrolizumab + Chemotherapy for Early TNBC
Slidesets KEYNOTE-826: Subgroup Analysis of Pembrolizumab + Chemotherapy ± Bevacizumab in Persistent, Recurrent, or Metastatic Cervical Cancer
Slidesets ENGOT Cx8/GOG 3024/innovaTV 205: Interim Phase II Results With Tisotumab Vedotin Combinations in Recurrent or Metastatic Cervical Cancer
Slidesets GARNET: Update From Phase I Trial of Dostarlimab in Patients With Advanced or Recurrent dMMR/MSI-H or pMMR/MSS Endometrial Cancer
Slidesets ORZORA: OS Results With Maintenance Olaparib in Platinum-Sensitive Relapsed Ovarian Cancer With a BRCA Mutation or Other HRR Mutation
Slidesets Relacorilant, a Selective Glucocorticoid Receptor Modulator, Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer: OS Analysis From a Randomized Phase II Trial
Slidesets TROPiCS-02: Phase III Trial of Sacituzumab Govitecan vs Physician’s Choice Treatment for HR+/HER2- Advanced Breast Cancer
Slidesets PALOMA-2 Final OS Analysis: Addition of Palbociclib to Frontline Letrozole in Postmenopausal ER+/HER2- Advanced Breast Cancer
Slidesets MAINTAIN: Phase II Study of Switching ET ± Ribociclib for HR+/HER2- Metastatic Breast Cancer After Failure of Previous ET + CDK4/6i
Slidesets DESTINY-Breast04: Trastuzumab Deruxtecan vs Physician’s Choice of Chemotherapy for Previously Treated HER2-Low Advanced Breast Cancer
Slidesets LUMINA: Local Recurrence With Omission of Radiotherapy After Breast-Conserving Surgery in T1N0 Luminal A Breast Cancer
Slidesets ATHENA-MONO: Phase III Trial of Maintenance Rucaparib vs Placebo After First-line Platinum-Based Chemotherapy in Advanced Ovarian Cancer
Slidesets MITO23: Phase III Trial of Trabectedin vs Investigator’s Choice of Chemotherapy for Recurrent Ovarian Cancer With BRCA Mutation or BRCAness Phenotype

Gain expert perspectives on the most clinically relevant data on breast and gynecologic cancers presented at the 2022 ASCO Annual Meeting.

Joyce O'Shaughnessy, MD Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: August 17, 2022 Expired: No longer available for credit
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Seagen & Genmab

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings